Atlas Trials

Understanding and Anticipating Therapeutic Response And Immuno-meDIated Adverse Events in Anti-cancer Immune-checkpoint Inhibition: a Tissue Biopsy Based imaGing Study

Clinical trial NCT05921123 · UNKNOWN

Trial details

NCT number
NCT05921123
Sponsor
University Hospital, Brest
Status
UNKNOWN
Study type
OBSERVATIONAL
Cancer
Start date
2023-11-25
Primary completion
2024-11-25
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.